GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Abstract
Tirzepatide (LY3298176), a dual GIP and GLP-1 receptor (GLP-1R) agonist, delivered superior glycemic control and weight loss compared with GLP-1R agonism in patients with type 2 diabetes. However, the mechanism by which tirzepatide improves efficacy and how GIP receptor (GIPR) agonism contributes is not fully understood. Here, we show that tirzepatide is an effective insulin sensitizer, improving insulin sensitivity in obese mice to a greater extent than GLP-1R agonism. To determine whether GIPR agonism contributes, we compared the effect of tirzepatide in obese WT and Glp-1r-null mice. In the absence of GLP-1R-induced weight loss, tirzepatide improved insulin sensitivity by enhancing glucose disposal in white adipose tissue (WAT). In support of this, a long-acting GIPR agonist (LAGIPRA) was found to enhance insulin sensitivity by augmenting glucose disposal in WAT. Interestingly, the effect of tirzepatide and LAGIPRA on insulin sensitivity was associated with reduced branched-chain amino acids (BCAAs) and ketoacids in the circulation. Insulin sensitization was associated with upregulation of genes associated with the catabolism of glucose, lipid, and BCAAs in brown adipose tissue. Together, our studies show that tirzepatide improved insulin sensitivity in a weight-dependent and -independent manner. These results highlight how GIPR agonism contributes to the therapeutic profile of dual-receptor agonism, offering mechanistic insights into the clinical efficacy of tirzepatide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, binding to the GLP-1 receptor also seems significant in tirzepatide’s cell surface receptor mechanism, as tirzepatide had no effect on body weight, food intake, fasting insulin levels, skeletal muscle, subcutaneous adipose tissue endogenous glucose production, or insulin-stimulated glucose uptake in GLP-1 receptor non-expressing knockout mice [93].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In preclinical studies, tirzepatide improved insulin sensitivity in GLP-1 receptor null mice, thus demonstrating the important role of GIP receptor agonism in insulin sensitization [9] in addition to contributions of both GLP-1 and GIP receptor agonism to glucose-dependent insulin secretion [10].”
From Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1). (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postprandial excursions of insulin drive glucose dis posal through actions in muscle and adipose tissue, along with effects of postprandial excursions in GIP, to enhance insulin sensitivity and augment glucose disposal in adipose tissue (2-5).”
From Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In GlP-1 R-null mice, tirzepatide improved insulin sensitivity by enhancing glucose disposal in white adipose tissue in the absence of GLP-1 RA-induced weight loss.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [169]
The cited source says what the claim attributes to it.
In the citing paper
“Murine studies indicate that GIP-dependent insulin sensitization of adipose tissue may be another major GIP action [122].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [122]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 17×
“Thus, while it is likely to make a smaller contribution in humans (compared with mice), our data suggest that BAT may aid weight-dependent mechanisms in the lowering of circulating lipids and BCAAs, enhancing the improvement of insulin sensitivity by tirzepatide in patients with T2DM (44, 52).”
BackgroundInfluentialIdentification and Importance of Brown Adipose Tissue in Adult Humans
Cypess, A. M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A. B., Kuo, F. C., Palmer, E. L., Tseng, Y.-H., Doria, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810780 · Cited by 4,399
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · cited 1×
“Although the cause of obesity-associated IR is intensely debated (4, 66, 67), recently, a strong association between elevated BCAAs/BCKAs, obesity, systemic IR, and T2DM has consistently been reported (66, 68).”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Unexpected evidence for active brown adipose tissue in adult humans
Nedergaard, J., Bengtsson, T., & Cannon, B. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00691.2006 · Cited by 1,824 · cited 1×
“Therefore, while BAT has classically been considered to have a limited effect on human metabolism (72, 73), studies show that adult humans have functional BAT (74), which when activated, is capable of positively affecting systemic metabolism (43, 75, 76).”
BackgroundBrown adipose tissue activity controls triglyceride clearance
Bartelt, A., Bruns, O. T., Reimer, R., Hohenberg, H., Ittrich, H., Peldschus, K., Kaul, M. G., Tromsdorf, U. I., Weller, H., Waurisch, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2297 · Cited by 1,608
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 1×
“The glycemic benefits associated with GLP-1RAs are due to enhanced β cell function, delayed gastric emptying, and weight loss–driven improvements in insulin sensitivity (9).”
Background
Cited by
Items 201–256 of 256
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Sarić, M. M., Šikić, N. L., Sorić, T., Sarić, A., Ivanišin, A., Brodić, I., & Milić, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125495 · Cited by 2
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
Takiyama, T., Kitsunai, H., Maruyama, F., Kitao, N., Wakabayashi, Y., Ito, M., Kurihara, H., Yamamoto, K., Takeuchi, J., Nanbu, T., et al. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109391 · Cited by 1
Twinkretin überzeugt bei Typ-2-Diabetes
Pampel, S. L. (2021) · Info Diabetologie · doi:10.1007/s15034-021-3734-9 · Cited by 1
Tirzépatide, sensibilité et sécrétion d’insuline
Andréelli, F. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.06.005 · Cited by 1
Manchanda, Y., Bitsi, S., Chen, S., Broichhagen, J., de la Serna, J. B., Jones, B. J., & Tomás, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.17.504231 · Cited by 1
Bellucci, A., Alfares, H., Gale, C., Akcan, M., Waters, B., Eisner, K., Baranowski, B. J., Jeromson, S., Babicki-Moore, A., & Wright, D. C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.21.727027 · Cited by 1
Müller, T. D. (2022) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-1904-5552
Ormoni gastrointestinali e terapia del diabete: dalla fisiologia alle nuove opportunità terapeutiche
Fadini, G. P. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01260-3 · Cited by 2
Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
Müller, T. D., & Blüher, M. (2023) · Gynäkologische Endokrinologie · doi:10.1007/s10304-023-00527-0
Vanweert, F. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231117fv · Cited by 1
Updates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004 · Cited by 1
Pointeau, O., Barbosa, R., Degrace, P., Vergès, B. L., & Jourdan, T. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.001
Maintaining Fat-Free Mass and Muscle Mass during obesity therapy with Incretin-Mimetic Drugs
Popiela, D., Urbańska, K., Stojak, Ł., Grego, M., Kwiatkowski, F., Baczewski, M., Grego, K., & Czyż, W. (2025) · Quality in Sport · doi:10.12775/qs.2025.37.57000 · Cited by 1
Highlights of the Most Recent American Diabetes Association Guidelines: From Evidence to Practice
Kim, M. K. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2329
Manchanda, Y., Desoki, R., Gardner, E. J., Perry, J. R. B., Wainscott, D. B., Stutsman, C., Langenberg, C., Coghlan, M. P., Bhatnagar, P., Ho, J. D., et al. (2025) · medRxiv · doi:10.1101/2025.08.15.25333807
Self-citationVarra, F., Varras, M. N., Varra, V., & Theodosis‐Nobelos, P. (2025) · Current Clinical Pharmacology · doi:10.2174/0127724328392698250818071803 · Cited by 3
Editorial: The impact of GIP/GIPR on metabolic diseases: how the field is evolving
Habegger, K. M., Tomás, A., Chen, R., Harris, C., Roell, W. C., & Coşkun, T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710843
Self-citationYamamori, D., Kitao, T., Masuda, S., Koike, S., Kaketaka, T., Komoda, Y., Nakano, E., Konishi, E., & Ibata, T. (2025) · Cureus · doi:10.7759/cureus.97279 · Cited by 1
Deng, Z., Zheng, D., Son, J., Du, W. J., McKimpson, W. M., Liu, Q., & Accili, D. (2025) · Acta Physiologica · doi:10.1111/apha.70141
Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Lejman, A., Mazurkiewicz, A., Sidor, H., Wołosik, M., & Zysiak, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4671
Li, J., Li, C., Yang, C., Zhu, Z., Ran, H., Liu, B., Zhang, Y., & Xiang, Y. (2026) · Peptides · doi:10.1016/j.peptides.2026.171489
The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes
Sun, L. L., Liu, H. F., Zhang, X., Zuo, F., Kong, Y., Feng, J., & Nian, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04534-2
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Salles, O. J. D. M., & de Oliveira, L. M. (2026) · Research Square · doi:10.21203/rs.3.rs-9783878/v1
The emerging role of branched-chain amino acid metabolism in obesity
Wang, D., Wang, X., & Yang, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02103-5
Heise, T., Zijlstra, E., Mari, A., Roell, W. C., Mather, K. J., Haupt, A., Flevaris, P., Liao, R., Chua, L., Harris, C., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70863
Self-citationTirzepatide: A Paradigm Shift in the Management of Type 2 Diabetes and Obesity
Sonawane, R. A., Gulave, O. K., Kale, P. A., & Rasal, P. B. (2026) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0092
Rennyson, K., Kenjale, A. A., Chiswell, K., Li, Y., Uchehara, B., Armstrong, S., Goldstein, B. A., Kelsey, M. D., Hurdle, M., McGarrah, R., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108369
Tanaka, Y., Ueno, H., Sawada, H., Konagata, A., Uchida, T., Uehira, Y., Kogo, F., Sekishima, A., Moritake, H., Yamaguchi, H., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1868458
Tirzepatide attenuates atherosclerosis through weight loss-independent anti-inflammatory mechanismsPreprint
Chen, S., Wei, S., Tian, T., Liu, Z. H., Su, M., Zhang, F.-S., Yin, Y., Chen, M., Jiang, L., Evans, P. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733886
Ciancimino, G., Pecorella, F., Viscardi, S. M., Mantia, C. L., Caserta, A., Pennisi, G., & Petta, S. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.19
Kitamoto, T., Yoshino, M., Shingaki, T., Oura, T., Valderas, E. G., & Dunn, J. P. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2695047
Mori, Y., Osaka, N., Terasaki, M., Yashima, H., Saito, T., Tanno, D., Ogino, M., Ohara, M., & Yamagishi, S. (2026) · Biomedicines · doi:10.3390/biomedicines14071554
Lipid sensing and brain hormone receptors in food intake and glucose regulation
Garrido, A. N., Lyons, S. A., MOSLEMIAN, D., Beaudry, J. L., & Lam, T. K. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01278-1
Li, J., Li, J., Xu, X., Wang, N., Lu, Y., & Wang, B. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03304-y
Reitz, J., Rosoff, D. B., Pacher, P., & Lohoff, F. W. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100793 · Cited by 1
Ruotolo, G., Harris, C., Lin, Y., Wilson, J. M., Pirro, V., Duffin, K. L., Thomas, M. K., Hartman, M. L., Neill, C. O., Coşkun, T., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71200 · Cited by 1
Self-citationHe, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
Manchanda, Y., Desoki, R., Gardner, E. J., Perry, J. R. B., Wainscott, D. B., Stutsman, C., Langenberg, C., Coghlan, M. P., Bhatnagar, P., Ho, J. D., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec3372
Self-citationBellucci, A., Alfares, H., Gale, C., Akcan, M., Waters, B., Eisner, K., Baranowski, B. J., Jeromson, S., Babicki-Moore, A., & Wright, D. C. (2026) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00220.2026
Abud, G. F., de Freitas, E. C., & Stanford, K. I. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00756-x
Patel, D., Ewida, H. A., Tareq, S., Aziz, M. T., Chelikani, P. K., Bickel, U., & Ahmed, M. S. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00404
Mahmoud, R., Yousif, A. A. Z., Osman, A. F. M., Omer, E. O. E., Talaat, A. I. A., Mohamed, O., Akasha, S. A. M., Saleh, E., & Osman, H. M. M. (2026) · Cureus · doi:10.7759/cureus.116733
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Andreeva-Gateva, P. A., Hristov, M., Nikolova, D. N., Bogdanov, I., Sabit, Z., & Dimova, I. I. (2026) · Diabetology · doi:10.3390/diabetology7100190
Lu, G., Wang, X., Zhuang, H., Wang, X., Zhou, X., & Zhao, G. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179387
Liu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
Molecular signaling networks that connect tissue dysfunction to systemic insulin resistance
Mir, R., Algehainy, N. A., Jalal, M. M., Altayar, M. A., Almotairi, R., Tayeb, F. J., Bedaiwi, R. I., Altemani, F. H., Almasoudi, K. S., Albalawi, I. A., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1952238
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
He, Y., Ma, T., 邢邯英, Cao, X., Song, F., Pan, Y., & Luping, R. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179418
Seo, Y., & Woo, J. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104843
Schwartzberg, E., Berman, E., Shani, S., Azran, C., Hagoel, R., Diker‐Cohen, T., & Dotan, I. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2756017
Grudniewska, A., Mrozikiewicz‐Rakowska, B., Wiszniewski, K., Filipiak, K. J., & Kuryłowicz, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219692
Metadata
- Authors
- Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., Furber, E. P. S. C., Ruan, X., O’Farrell, L. S., Long, A. M., Dogra, M., Willency, J. A., Lin, Y., Ding, L., Cheng, C. C., Cabrera, O., Briere, D. A., Alsina-Fernandez, J., Gimeno, R. E., Moyers, J. S., Coskun, T., Coghlan, M. P., Sloop, K. W., & Roell, W. C.
- Affiliations
- Eli Lilly (United States) (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2021-06-15
- Volume
- 131
- Issue
- 12
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC8203452
- OpenAlex
- W3161292733
- Cited by
- 256
- References
- 82
- Citations by year
- 2026: 58 · 2025: 66 · 2024: 54 · 2023: 34 · 2022: 34 · 2021: 10
- FWCI
- 24.64
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- tirzepatide, GLP-1 receptor agonism, insulin sensitization, obesity, type 2 diabetes, glucose disposal, white adipose tissue, brown adipose tissue, branched-chain amino acids, keto acids
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Amino Acids, Branched-Chain, Animals, Body Weight, Gastric Inhibitory Polypeptide, Insulin Resistance, Obesity, Mice, Knockout, Mice, Adipose Tissue, White
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.